Publication | Closed Access

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Phase 1/2Lymphoid NeoplasiaHematological MalignancyBcl-2 InhibitorMedicineImmunologyHematologyPathologyAdult T-cell Leukemia-lymphomaOncologyCancer ResearchJapanese Patients